Clinical trial · people

Retatrutide 12 mg: UACR 37.0% lower vs placebo in type 2 diabetes

Checked against the paper Clinical trialPublished by PepVault

The takeaway

In these trials, higher retatrutide doses were linked to less albumin in the urine, and to higher eGFR in people with obesity but not in people with type 2 diabetes, in groups where most started with normal albumin levels.

Kind
Clinical trial
Studied in
People
Published
2025
Journal
Kidney Int Rep

What they tested

The team wanted to know how retatrutide changes kidney measures in people with type 2 diabetes, or with overweight or obesity.

How the study was done

A post hoc analysis, meaning one planned after the fact, of 2 placebo-controlled trials with doses from 0.5 to 12 mg: 281 people with type 2 diabetes over 36 weeks, with a dulaglutide 1.5 mg comparison group, and 338 people with overweight or obesity but no diabetes over 48 weeks. Everyone had an eGFR (a measure of how well the kidneys filter blood) of at least 45 ml/min per 1.73 m2.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In people with type 2 diabetes, the 12 mg arm had UACR (the urine albumin-to-creatinine ratio, a measure of albumin in the urine) 37.0% lower than placebo at 36 weeks (95% CI: -57.3 to -7.0), while eGFR did not change compared with placebo. In people with overweight or obesity, UACR was 28.0% lower in the 8 mg arm and 31.5% lower in the 12 mg arm than placebo at 48 weeks. In that group, eGFR based on creatinine rose by 5.3 ml/min per 1.73 m2 in the 8 mg arm and 8.5 ml/min per 1.73 m2 in the 12 mg arm, and eGFR based on cystatin C, or on both markers combined, rose by a similar amount.

What it doesn’t show

This was a post hoc analysis, and most people started with normal albumin levels (median UACR of 13 mg/g and 7 mg/g), so the drop in actual albumin amounts was modest. People with eGFR below 45 were not included.

The paper

Heerspink et al. The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity. Kidney Int Rep. 2025.

The compound

More studies on Retatrutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo